-
1
-
-
0034727820
-
Managing depression in medical outpatients
-
Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med 2000;343:1942-50.
-
(2000)
N Engl J Med
, vol.343
, pp. 1942-1950
-
-
Whooley, M.A.1
Simon, G.E.2
-
3
-
-
0003130575
-
Depression in the workplace: An economic perspective
-
Feighner JP, Boyer WF, eds. New York: John Wiley & Sons
-
Greenberg PE, Kessler RC, Nells TL, Finkelstein SN, Berndt ER. Depression in the workplace: an economic perspective. In: Feighner JP, Boyer WF, eds. Selective serotonin re-uptake inhibitors: advances in basic research and clinical practice, 2nd ed. New York: John Wiley & Sons, 1996:327-63.
-
(1996)
Selective Serotonin Re-uptake Inhibitors: Advances in Basic Research and Clinical Practice, 2nd Ed.
, pp. 327-363
-
-
Greenberg, P.E.1
Kessler, R.C.2
Nells, T.L.3
Finkelstein, S.N.4
Berndt, E.R.5
-
4
-
-
1242338645
-
The economic burden of depression in the United States: How did it change between 1990 and 2000?
-
Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-75.
-
(2003)
J Clin Psychiatry
, vol.64
, pp. 1465-1475
-
-
Greenberg, P.E.1
Kessler, R.C.2
Birnbaum, H.G.3
-
5
-
-
0003433982
-
-
Cambridge, MA: Harvard School of Public Health on behalf of the World Health Organization and the World Bank, Harvard University Press
-
Murray CJL, Lopez AD, eds. The global burden of disease and injury series, volume 1: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard School of Public Health on behalf of the World Health Organization and the World Bank, Harvard University Press, 1996.
-
(1996)
The Global Burden of Disease and Injury Series, Volume 1: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020
, vol.1
-
-
Murray, C.J.L.1
Lopez, A.D.2
-
6
-
-
0004235298
-
-
text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association
-
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed., text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
-
(2000)
Diagnostic and Statistical Manual of Mental Disorders, 4th Ed.
-
-
-
7
-
-
0034030898
-
Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association
-
Gelenberg A, Merriam A, Karasu TB, Wang P. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000;157(suppl 4):1-45.
-
(2000)
Am J Psychiatry
, vol.157
, Issue.SUPPL. 4
, pp. 1-45
-
-
Gelenberg, A.1
Merriam, A.2
Karasu, T.B.3
Wang, P.4
-
8
-
-
0036238595
-
Does depression hurt?
-
Stahl SM. Does depression hurt? J Clin Psychiatry 2002;63:273-4.
-
(2002)
J Clin Psychiatry
, vol.63
, pp. 273-274
-
-
Stahl, S.M.1
-
9
-
-
0036192893
-
Unmet need: What justifies the search for a new antidepressant?
-
Greden JF. Unmet need: what justifies the search for a new antidepressant? J Clin Psychiatry 2002;63(suppl 2):3-7.
-
(2002)
J Clin Psychiatry
, vol.63
, Issue.SUPPL. 2
, pp. 3-7
-
-
Greden, J.F.1
-
10
-
-
0036240501
-
Somatic symptoms, depression, and antidepressant treatment
-
Fava M. Somatic symptoms, depression, and antidepressant treatment. J Clin Psychiatry 2002;63:305-7.
-
(2002)
J Clin Psychiatry
, vol.63
, pp. 305-307
-
-
Fava, M.1
-
11
-
-
0028156958
-
Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the national comorbidity survey
-
Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity survey. Arch Gen Psychiatry 1994;51:8-19.
-
(1994)
Arch Gen Psychiatry
, vol.51
, pp. 8-19
-
-
Kessler, R.C.1
McGonagle, K.A.2
Zhao, S.3
-
12
-
-
0034099071
-
A 40-year perspective on the prevalence of depression: The Stirling County study
-
Murphy JA, Laird NM, Monson RR, Sobol AM, Leighton AH. A 40-year perspective on the prevalence of depression: the Stirling County study. Arch Gen Psychiatry 2000;57:209-15.
-
(2000)
Arch Gen Psychiatry
, vol.57
, pp. 209-215
-
-
Murphy, J.A.1
Laird, N.M.2
Monson, R.R.3
Sobol, A.M.4
Leighton, A.H.5
-
13
-
-
0023787325
-
One month prevalence of mental disorders in the United States: Based on five epidemiologic catchment area sites
-
Regier DA, Boyd JH, Burke JD Jr, et al. One month prevalence of mental disorders in the United States: based on five epidemiologic catchment area sites. Arch Gen Psychiatry 1988;45:977-86.
-
(1988)
Arch Gen Psychiatry
, vol.45
, pp. 977-986
-
-
Regier, D.A.1
Boyd, J.H.2
Burke Jr., J.D.3
-
14
-
-
0037848861
-
Depressive disorders
-
DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. New York: McGraw-Hill
-
Kando JC, Wells BG, Hayes PE. Depressive disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 5th ed. New York: McGraw-Hill, 2002:1243-5.
-
(2002)
Pharmacotherapy: A Pathophysiologic Approach, 5th Ed.
, pp. 1243-1245
-
-
Kando, J.C.1
Wells, B.G.2
Hayes, P.E.3
-
15
-
-
0036257156
-
The psychopharmacology of painful physical symptoms in depression
-
Stahl SM. The psychopharmacology of painful physical symptoms in depression. J Clin Psychiatry 2002;63:382-3.
-
(2002)
J Clin Psychiatry
, vol.63
, pp. 382-383
-
-
Stahl, S.M.1
-
17
-
-
14544295675
-
Psychiatric disorders
-
Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. New York: McGraw-Hill
-
Reus VJ. Psychiatric disorders. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine, 15th ed. New York: McGraw-Hill, 2001:2549.
-
(2001)
Harrison's Principles of Internal Medicine, 15th Ed.
, pp. 2549
-
-
Reus, V.J.1
-
18
-
-
0018425438
-
A new depression scale designed to be sensitive to change
-
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
-
(1979)
Br J Psychiatry
, vol.134
, pp. 382-389
-
-
Montgomery, S.A.1
Asberg, M.2
-
20
-
-
0032901376
-
The Texas medication algorithm project: Report of the Texas consensus conference panel on the treatment of major depressive disorder
-
Crismon ML, Trivedi M, Pigott TA, et al. The Texas medication algorithm project: report of the Texas consensus conference panel on the treatment of major depressive disorder. J Clin Psychiatry 1999;60:142-56.
-
(1999)
J Clin Psychiatry
, vol.60
, pp. 142-156
-
-
Crismon, M.L.1
Trivedi, M.2
Pigott, T.A.3
-
21
-
-
0029967073
-
Definition and epidemiology of treatment-resistant depression
-
Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200.
-
(1996)
Psychiatr Clin North Am
, vol.19
, pp. 179-200
-
-
Fava, M.1
Davidson, K.G.2
-
22
-
-
0035103243
-
Sustained response to open-label venlafaxine in drug resistant major depression
-
Schweitzer I, Burrows G, Tuckwell V, et al. Sustained response to open-label venlafaxine in drug resistant major depression. J Clin Psychopharmacol 2001;21:185-9.
-
(2001)
J Clin Psychopharmacol
, vol.21
, pp. 185-189
-
-
Schweitzer, I.1
Burrows, G.2
Tuckwell, V.3
-
23
-
-
0034894282
-
Efficacy and safety of mirtazepine in major depressive disorder patients after SSRI treatment failure: An open label trial
-
Fava M, Dunner DL, Greist JH, et al. Efficacy and safety of mirtazepine in major depressive disorder patients after SSRI treatment failure: an open label trial. J Clin Psychiatry 2001;62:413-20.
-
(2001)
J Clin Psychiatry
, vol.62
, pp. 413-420
-
-
Fava, M.1
Dunner, D.L.2
Greist, J.H.3
-
24
-
-
0031046973
-
Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline
-
Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997;58:16-21.
-
(1997)
J Clin Psychiatry
, vol.58
, pp. 16-21
-
-
Thase, M.E.1
Blomgren, S.L.2
Birkett, M.A.3
Apter, J.T.4
Tepner, R.G.5
-
25
-
-
0025829243
-
A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression
-
Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI. A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-7.
-
(1991)
Arch Gen Psychiatry
, vol.48
, pp. 303-307
-
-
Nelson, J.C.1
Mazure, C.M.2
Bowers Jr., M.B.3
Jatlow, P.I.4
-
26
-
-
1642523483
-
Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomized study
-
Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004;55:296-300.
-
(2004)
Biol Psychiatry
, vol.55
, pp. 296-300
-
-
Nelson, J.C.1
Mazure, C.M.2
Jatlow, P.I.3
Bowers Jr., M.B.4
Price, L.H.5
-
27
-
-
0036261230
-
Efficacy and tolerability of venlafaxine, selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis
-
Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine, selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404.
-
(2002)
Br J Psychiatry
, vol.180
, pp. 396-404
-
-
Smith, D.1
Dempster, C.2
Glanville, J.3
Freemantle, N.4
Anderson, I.5
-
28
-
-
0035111499
-
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
-
Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41.
-
(2001)
Br J Psychiatry
, vol.178
, pp. 234-241
-
-
Thase, M.E.1
Entsuah, A.R.2
Rudolph, R.L.3
-
29
-
-
0031960136
-
Selective serotonin reuptake inhibitors vs tricyclic antidepressants in depressed patients: A meta-analysis of efficacy and tolerability
-
Anderson IM. Selective serotonin reuptake inhibitors vs tricyclic antidepressants in depressed patients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998;7(suppl):11-17.
-
(1998)
Depress Anxiety
, vol.7
, Issue.SUPPL.
, pp. 11-17
-
-
Anderson, I.M.1
-
30
-
-
0035137253
-
Amitriptyline v. the rest: Still the leading antidepressant after 40 years of randomized controlled trials
-
Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomized controlled trials. Br J Psychiatry 2001;178:129-44.
-
(2001)
Br J Psychiatry
, vol.178
, pp. 129-144
-
-
Barbui, C.1
Hotopf, M.2
-
31
-
-
0033059545
-
Venlafaxine and paroxetine in treatment-resistant depression: Double-blind, randomised comparison
-
Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry 1999;175:12-16.
-
(1999)
Br J Psychiatry
, vol.175
, pp. 12-16
-
-
Poirier, M.F.1
Boyer, P.2
-
32
-
-
0036673979
-
Combining antidepressants for treatment resistant depression: A review
-
Lam RW, Wan DD, Cohen NL, Kennedy SH. Combining antidepressants for treatment resistant depression: a review. J Clin Psychiatry 2002;63:685-93.
-
(2002)
J Clin Psychiatry
, vol.63
, pp. 685-693
-
-
Lam, R.W.1
Wan, D.D.2
Cohen, N.L.3
Kennedy, S.H.4
-
33
-
-
0035111499
-
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
-
Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41.
-
(2001)
Br J Psychiatry
, vol.178
, pp. 234-241
-
-
Thase, M.E.1
Entsuah, A.R.2
Rudolph, R.L.3
-
34
-
-
0033927251
-
Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment resistant major depression
-
Mitchell PB, Schweitzer I, Burrows G, Johnson G, Polonowita A. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment resistant major depression. J Clin Psychopharmacol 2000;20:483-7.
-
(2000)
J Clin Psychopharmacol
, vol.20
, pp. 483-487
-
-
Mitchell, P.B.1
Schweitzer, I.2
Burrows, G.3
Johnson, G.4
Polonowita, A.5
-
35
-
-
0026410099
-
The use of antidepressants in the treatment of chronic pain
-
Magni G. The use of antidepressants in the treatment of chronic pain. Drugs 1991;42:730-48.
-
(1991)
Drugs
, vol.42
, pp. 730-748
-
-
Magni, G.1
-
36
-
-
0033677869
-
Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: A quantitative systematic review
-
Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 2000;20:449-58.
-
(2000)
J Pain Symptom Manage
, vol.20
, pp. 449-458
-
-
Collins, S.L.1
Moore, R.A.2
McQuay, H.J.3
Wiffen, P.4
-
37
-
-
0029093439
-
Simultaneous increases in extra cellular monoamines in microdialysates from the hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor
-
Engleman EA, Perry KW, Mayle DA, Wong DT. Simultaneous increases in extra cellular monoamines in microdialysates from the hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology 1995;12:287-95.
-
(1995)
Neuropsychopharmacology
, vol.12
, pp. 287-295
-
-
Engleman, E.A.1
Perry, K.W.2
Mayle, D.A.3
Wong, D.T.4
-
39
-
-
0027475388
-
LY248686, a new inhibitor of serotonin and norepinephrine
-
Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW. LY248686, a new inhibitor of serotonin and norepinephrine. Neuropsychopharmacology 1993;8:23-33.
-
(1993)
Neuropsychopharmacology
, vol.8
, pp. 23-33
-
-
Wong, D.T.1
Bymaster, F.P.2
Mayle, D.A.3
Reid, L.R.4
Krushinski, J.H.5
Robertson, D.W.6
-
40
-
-
0035079542
-
Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects
-
Turcotte JE, Debonnel G, de Montigny C, Hebert C, Blier P. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 2001;24:511-21.
-
(2001)
Neuropsychopharmacology
, vol.24
, pp. 511-521
-
-
Turcotte, J.E.1
Debonnel, G.2
De Montigny, C.3
Hebert, C.4
Blier, P.5
-
41
-
-
85058248172
-
Duloxetine, clinical evidence the tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition
-
Chalon S, Bieck PR, Goldstein DJ, et al. Duloxetine, clinical evidence the tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition. Neuropsychopharmacology 2002;26:698-701.
-
(2002)
Neuropsychopharmacology
, vol.26
, pp. 698-701
-
-
Chalon, S.1
Bieck, P.R.2
Goldstein, D.J.3
-
42
-
-
0026348807
-
Pre-synaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments: An in vivo electrophysiologic study in the rat
-
Chaput Y, de Montigny C, Blier P. Pre-synaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments: an in vivo electrophysiologic study in the rat. Neuropsychopharmacology 1991;5:219-29.
-
(1991)
Neuropsychopharmacology
, vol.5
, pp. 219-229
-
-
Chaput, Y.1
De Montigny, C.2
Blier, P.3
-
43
-
-
0028328482
-
Electrophysiologic evidence for desensitization of the α-2 adrenoreceptors on serotonin terminals following long-term treatment with drugs increasing norepinephrine synaptic concentration
-
Mongeau R, de Montigny C, Blier P. Electrophysiologic evidence for desensitization of the α-2 adrenoreceptors on serotonin terminals following long-term treatment with drugs increasing norepinephrine synaptic concentration. Neuropsychopharmacology 1994;10:41-51.
-
(1994)
Neuropsychopharmacology
, vol.10
, pp. 41-51
-
-
Mongeau, R.1
De Montigny, C.2
Blier, P.3
-
44
-
-
0024347556
-
Modulation of neurotransmitter release by presynaptic autoreceptors
-
Starke K, Gothert M, Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 1989;69:864-988.
-
(1989)
Physiol Rev
, vol.69
, pp. 864-988
-
-
Starke, K.1
Gothert, M.2
Kilbinger, H.3
-
45
-
-
0032509709
-
WAY100,635 enhances both the antidepressant actions of duloxetine and its influence on dialysate levels of serotonin in the frontal cortex
-
Millan MJ, Brocco M, Veiga S, Cistarelli L, Mellon C, Gobert A. WAY100,635 enhances both the antidepressant actions of duloxetine and its influence on dialysate levels of serotonin in the frontal cortex. Eur J Pharmacol 1998;341:165-7.
-
(1998)
Eur J Pharmacol
, vol.341
, pp. 165-167
-
-
Millan, M.J.1
Brocco, M.2
Veiga, S.3
Cistarelli, L.4
Mellon, C.5
Gobert, A.6
-
47
-
-
2942594466
-
Synthesis and biologic activity of some known putative duloxetine metabolites
-
Kuo F, Gillespie TA, Kulanthaivel P, et al. Synthesis and biologic activity of some known putative duloxetine metabolites. Bioorg Med Chem Lett 2004;14:3481-6.
-
(2004)
Bioorg Med Chem Lett
, vol.14
, pp. 3481-3486
-
-
Kuo, F.1
Gillespie, T.A.2
Kulanthaivel, P.3
-
49
-
-
0032524235
-
Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters
-
Beique JC, Lavoie N, de Montigny C, Debonnel G. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol 1998;349:129-32.
-
(1998)
Eur J Pharmacol
, vol.349
, pp. 129-132
-
-
Beique, J.C.1
Lavoie, N.2
De Montigny, C.3
Debonnel, G.4
-
50
-
-
0031003936
-
Electrophysiological effects of fluoxetine and duloxetine in the dorsal raphe nucleus and hippocampus
-
Smith JE, Lakoski JM. Electrophysiological effects of fluoxetine and duloxetine in the dorsal raphe nucleus and hippocampus. Eur J Pharmacol 1997;323:69-73.
-
(1997)
Eur J Pharmacol
, vol.323
, pp. 69-73
-
-
Smith, J.E.1
Lakoski, J.M.2
-
51
-
-
0035677108
-
Comparative efficacy of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors
-
Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative efficacy of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropharmacology 2001;25:871-80.
-
(2001)
Neuropharmacology
, vol.25
, pp. 871-880
-
-
Bymaster, F.P.1
Dreshfield-Ahmad, L.J.2
Threlkeld, P.G.3
-
52
-
-
0003852257
-
-
Publication no. 99-E014. Evidence report/technology assessment no. 7. Rockville, MD: Agency of Health Care Policy and Research, U.S. Department of Health and Human Services
-
Williams JW, Trivedi M, Chiquette E, et al. Treatment of depression: newer pharmacotherapies. Publication no. 99-E014. Evidence report/technology assessment no. 7. Rockville, MD: Agency of Health Care Policy and Research, U.S. Department of Health and Human Services, 1999.
-
(1999)
Treatment of Depression: Newer Pharmacotherapies
-
-
Williams, J.W.1
Trivedi, M.2
Chiquette, E.3
-
53
-
-
0030613812
-
2-Adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenalin, dopamine, and serotonin levels in the frontal cortex of freely moving rats
-
2-Adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenalin, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J Neurochem 1997;69:2616-19.
-
(1997)
J Neurochem
, vol.69
, pp. 2616-2619
-
-
Gobert, A.1
Rivet, J.M.2
Cistarelli, L.3
Melon, C.4
Millan, M.J.5
-
54
-
-
0031017894
-
Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats
-
Gobert A, Rivet JM, Cistarelli L, Millan MJ. Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J Neurochem 1997;68:1326-9.
-
(1997)
J Neurochem
, vol.68
, pp. 1326-1329
-
-
Gobert, A.1
Rivet, J.M.2
Cistarelli, L.3
Millan, M.J.4
-
55
-
-
0033674519
-
Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor
-
Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000;40:161-7.
-
(2000)
J Clin Pharmacol
, vol.40
, pp. 161-167
-
-
Sharma, A.1
Goldberg, M.J.2
Cerimele, B.J.3
-
56
-
-
0037374043
-
Duloxetine is both an inhibitor and a substrate of cytochrome P450 2D6 in healthy volunteers
-
Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther 2003;73:170-7.
-
(2003)
Clin Pharmacol Ther
, vol.73
, pp. 170-177
-
-
Skinner, M.H.1
Kuan, H.Y.2
Pan, A.3
-
57
-
-
0002471005
-
The effect of food and bedtime administration on duloxetine pharmacokinetics
-
Skinner MH, Skerjanec A, Seger M, Hewitt R. The effect of food and bedtime administration on duloxetine pharmacokinetics [abstr]. Clin Pharmacol Ther 2000;67:129.
-
(2000)
Clin Pharmacol Ther
, vol.67
, pp. 129
-
-
Skinner, M.H.1
Skerjanec, A.2
Seger, M.3
Hewitt, R.4
-
58
-
-
0347319049
-
Effect of age on the pharmacokinetics of duloxetine in women
-
Skinner MH, Kuan HY, Skerjanec A, et al. Effect of age on the pharmacokinetics of duloxetine in women. Br J Clin Pharmacol 2004;57:54-61.
-
(2004)
Br J Clin Pharmacol
, vol.57
, pp. 54-61
-
-
Skinner, M.H.1
Kuan, H.Y.2
Skerjanec, A.3
-
59
-
-
0030844643
-
An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenalin reuptake inhibitor, in patients with DSM-III-R major depressive disorder
-
Berk M, du Plessis AD, Birkett M, Richardt D. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenalin reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Int Clin Psychopharmacol 1997;12:137-40.
-
(1997)
Int Clin Psychopharmacol
, vol.12
, pp. 137-140
-
-
Berk, M.1
Du Plessis, A.D.2
Birkett, M.3
Richardt, D.4
-
60
-
-
0036232639
-
Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial
-
Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-15.
-
(2002)
J Clin Psychiatry
, vol.63
, pp. 308-315
-
-
Detke, M.J.1
Lu, Y.2
Goldstein, D.J.3
Hayes, J.R.4
Demitrack, M.A.5
-
61
-
-
0036829053
-
Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
-
Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psych Res 2002;36:383-90.
-
(2002)
J Psych Res
, vol.36
, pp. 383-390
-
-
Detke, M.J.1
Lu, Y.2
Goldstein, D.J.3
McNamara, R.K.4
Demitrack, M.A.5
-
62
-
-
0036112313
-
Duloxetine in the treatment of major depressive disorder: A double blind clinical trial
-
Goldstein DJ, Mallinchrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double blind clinical trial. J Clin Psychiatry 2002;63:225-31.
-
(2002)
J Clin Psychiatry
, vol.63
, pp. 225-231
-
-
Goldstein, D.J.1
Mallinchrodt, C.2
Lu, Y.3
Demitrack, M.A.4
-
63
-
-
3242707697
-
Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine
-
Goldstein DJ, Lu Y, Detke MJ, Wilste C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-99.
-
(2004)
J Clin Psychopharmacol
, vol.24
, pp. 389-399
-
-
Goldstein, D.J.1
Lu, Y.2
Detke, M.J.3
Wilste, C.4
Mallinckrodt, C.5
Demitrack, M.A.6
-
65
-
-
41549115932
-
Remission in placebo-controlled trials of duloxetine with an SSRI comparator
-
San Francisco; CA, May 17-22
-
Thase ME, Lu Y, Joliat MJ, Detke MJ. Remission in placebo-controlled trials of duloxetine with an SSRI comparator. Poster presentation at the 156th annual meeting of the American Psychiatric Association, San Francisco; CA, May 17-22, 2003.
-
(2003)
Poster Presentation at the 156th Annual Meeting of the American Psychiatric Association
-
-
Thase, M.E.1
Lu, Y.2
Joliat, M.J.3
Detke, M.J.4
-
66
-
-
0346463249
-
Effects of duloxetine on painful physical symptoms associated with depression
-
Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004;45:17-28.
-
(2004)
Psychosomatics
, vol.45
, pp. 17-28
-
-
Goldstein, D.J.1
Lu, Y.2
Detke, M.J.3
Hudson, J.4
Iyengar, S.5
Demitrack, M.A.6
-
67
-
-
0031965568
-
The visual analogue scale in the immediate postoperative period: Intrasubject variation and correlation of a numeric scale
-
DeLoach LJ, Higgins MS, Caplan AB, Stiff JL. The visual analogue scale in the immediate postoperative period: intrasubject variation and correlation of a numeric scale. Anesth Analg 1998;86:102-6.
-
(1998)
Anesth Analg
, vol.86
, pp. 102-106
-
-
DeLoach, L.J.1
Higgins, M.S.2
Caplan, A.B.3
Stiff, J.L.4
-
68
-
-
0038186563
-
Effect of duloxetine (DU) on CYP1A2-medicated drug metabolism and the pharmacokinetics (PK) of theophylline (THEO)
-
Di Virgilio SN, Gonzales C, Knadler MP, Kuan H, Skinner MH, Decourt J. Effect of duloxetine (DU) on CYP1A2-medicated drug metabolism and the pharmacokinetics (PK) of theophylline (THEO) [abstr]. Clin Pharmacol Ther 2002;71: P63.
-
(2002)
Clin Pharmacol Ther
, vol.71
-
-
Di Virgilio, S.N.1
Gonzales, C.2
Knadler, M.P.3
Kuan, H.4
Skinner, M.H.5
Decourt, J.6
-
69
-
-
0037848857
-
Duloxetine dose not exacerbate the effects of alcohol on psychometric tests
-
Skinner MH, Weerakkody G. Duloxetine dose not exacerbate the effects of alcohol on psychometric tests [abstr]. Clin Pharmacol Ther 2002;71:P53.
-
(2002)
Clin Pharmacol Ther
, vol.71
-
-
Skinner, M.H.1
Weerakkody, G.2
|